VINCIT: A virus-incorporated biomaterial niche enables spatially controlled in vivo CAR T cell engineering
In vivo generation of chimeric antigen receptor (CAR) T cells could bypass the complex manufacturing required for conventional cell therapies, but systemic gene delivery remains limited by off target exposure and inefficient access to target immune cells. Here, we develop VINCIT (Virus Incorporated Niche for Cellular ImmunoTherapy), an injectable nanofiber hydrogel composite that establishes a localized immune-engineering niche for CAR T cell generation in vivo. VINCIT spatially retains viral vectors while recruiting endogenous immune cells, enabling local transduction of T cells, after which the engineered T cells enter the circulation. VINCIT spatially confines transgene expression compared with intravenous viral delivery and markedly enhances T cell transduction compared with subcutaneously injected free virus. VINCIT is compatible with both adeno-associated and lentiviral vectors, and CAR T cells generated in vivo exhibit antigen-specific effector responses and mediate CD19+ B cell depletion. In a humanized mouse model of lymphoma, a single VINCIT administration produces sustained tumor control and extends median survival from 32 to 110 days. Mechanistically, efficient CAR T cell generation requires coordinated interactions among multiple immune populations, with neutrophil depletion markedly reducing cellular recruitment and subsequent T cell programming. These findings establish a localized biomaterial niche for spatially controlled in vivo immune cell engineering.
Authors
- Christine Wei
- Yining Zhu (ORCID: https://orcid.org/0000-0002-7178-0097)
- Hai‐Quan Mao (ORCID: https://orcid.org/0000-0002-4262-9988)
- Autumn H. Greco (ORCID: https://orcid.org/0000-0002-7557-6800)
- Yunhe Su (ORCID: https://orcid.org/0009-0007-6319-7858)
- Maximilian F. Konig (ORCID: https://orcid.org/0000-0001-5045-5255)
- Jiayuan Kong (ORCID: https://orcid.org/0000-0002-5368-8940)
- Jonathan P. Schneck (ORCID: https://orcid.org/0000-0001-5346-2776)
- Joseph Choy (ORCID: https://orcid.org/0000-0001-6282-9437)
- Joshua C. Doloff (ORCID: https://orcid.org/0000-0002-4323-3264)
- Jingyao Ma (ORCID: https://orcid.org/0009-0003-8848-7502)
- Kailei D. Goodier (ORCID: https://orcid.org/0009-0008-2397-2079)
- YIli Jiang
- Sabrina Chen (ORCID: https://orcid.org/0000-0002-4771-4436)
- Zhuoqing Jiang
- Dylan Luong
- Evan Wang
- Jinghan Lin
- Xiang Liu
- Di Yu
- D Scott Wilson
- Xiaoya Lu
Institutions
- Johns Hopkins University (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.64898/2026.11.16.767176
- Primary Topic
- CAR-T cell therapy research
- Type
- preprint
Funders
- National Institutes of Health
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases